June 25, 2025 | BALTIMORE – We are thrilled to share that a major milestone in cell therapy has just been published in Cell, showcasing the world’s first-in-human clinical study of dual-targeting CAR-NK cells derived from induced pluripotent stem cells (iPSCs). The therapy demonstrated promising efficacy with an excellent safety profile—no signs of cytokine release syndrome (CRS), neurotoxicity, or graft-versus-host disease (GvHD). This represents a paradigm shift toward scalable, off-the-shelf immune cell therapy solutions. — But what powers the safety, monitoring, and mechanistic understanding behind such a novel therapy? The answer lies in Complete360®, our proprietary clinical-grade deep plasma proteomics platform.
